| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Soliton, Inc., (NASDAQ:SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced the launch of its highly anticipated Rapid Acoustic Pulse™ (RAP) device — RESONIC™. The dual-platform RESONIC™ device utilizes a first-of-its-kind technology and offers a paradigm-shifting approach to two in-demand procedures: tattoo removal and cellulite treatment. Harnessing the power of sound, RESONIC helps achieve 75% greater fading of tattoos in as few as 3 sessions and improves the appearance of cellulite non-invasively with high patient satisfaction after just 1 treatment session.
"This is an exciting day for Soliton and the RESONIC brand," shared Brad Hauser, President & CEO of Soliton. "It's been a long time in the making and we're excited to finally bring this innovative and efficacious solution to procedures that have had historically low patient satisfaction or required numerous treatment sessions to achieve expected results. Launching RESONIC with two unique indications has been a strategic goal of ours since receiving our first FDA clearance in 2019. This approach enables our HCP partners to drive multiple revenue streams among two different patient profiles with one device, positioning our partners for accelerated practice growth, and poising RESONIC to become a leading aesthetics brand," added Hauser.
Leveraging its proprietary technology, the RESONIC device is designed to safely deliver rapid, high-pressure acoustic shockwaves at a rate of up to 100 pulses per second, resulting in the physical change of targeted cellular structures without creating cavitation or heating that could result in surrounding tissue damage. The Rapid Acoustic Pulse technology creates a new standard in tattoo removal when used as an accessory to a Q-Switched laser, to allow for multiple laser passes and up to 44% fading in a single session with tattoo removal in as few as 3 sessions. This innovative technology also safely and non-invasively physically changes fibrous septa bands beneath the skin that cause cellulite to deliver efficacious results in just one, 45–60-minute treatment with minimal discomfort and without downtime.
"RESONIC revolutionizes the industry's approach to two notoriously challenging patient needs. The technology's ability to physically change targeted cellular structures without breaking the skin is game changing," shared Dr. Elizabeth Tanzi, Board Certified Dermatologist and member of Soliton's Scientific Advisory Board. "Clinical trial results for both RESONIC procedures showed significant results with accelerated treatment timelines, which I believe will result in higher patient satisfaction and will minimize common barriers to entry that exist for tattoo removal and cellulite reduction."
RESONIC is cleared by the U.S. Food and Drug Administration (FDA) as an accessory to the 1064 nm Q-Switched laser for black ink tattoo removal in Fitzpatrick Skin Type I-III patients and short-term improvement in the appearance of cellulite.
RESONIC for Tattoo and RESONIC for Cellulite will be available through a select network of physicians and medically supervised spas beginning in June 2021. Visit http://www.RESONIC.com/ for more information and to find a physician near you.
Posted In: SOLY
